Latest News on ANAB

Financial News Based On Company


Advertisement
Advertisement

Form 4 AnaptysBio Inc: EcoR1 Capital, LLC (Director, 10% Owner) For: 16 November

https://ca.investing.com/news/stock-market-news/form-4-anaptysbio-inc-ecor1-capital-llc-director-10-owner-for-16-november-93CH-4968245
This article reports on a Form 4 filing for AnaptysBio Inc, detailing that EcoR1 Capital, LLC, a Director and 10% Owner, had a transaction on November 16. The content notes the date of the filing but does not provide specific details of the transaction itself.

There Are Some Holes In AnaptysBio's (NASDAQ:ANAB) Solid Earnings Release

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-anab/anaptysbio/news/there-are-some-holes-in-anaptysbios-nasdaqanab-solid-earning
AnaptysBio, Inc. reported healthy profits, but investors seem unimpressed due to several concerning factors. The company's high accrual ratio indicates that profit isn't well-backed by free cash flow, and it experienced negative free cash flow. Additionally, AnaptysBio diluted existing shareholders by issuing new shares, negatively impacting earnings per share.

Form 4 AnaptysBio Inc: EcoR1 Capital, LLC (Director, 10% Owner) For: 16 November

https://uk.investing.com/news/stock-market-news/form-4-anaptysbio-inc-ecor1-capital-llc-director-10-owner-for-16-november-93CH-4991924
This article reports on a Form 4 filing for AnaptysBio Inc, indicating that EcoR1 Capital, LLC, a director and 10% owner, made a transaction on November 16. The brief piece primarily serves as an announcement of this regulatory filing.

AnaptysBio (ANABV) director EcoR1 Capital bought 374,580 shares for $17.2M at an average $45.98

https://quantisnow.com/insight/director-ecor1-capital-llc-bought-17224593-worth-of-shares-374580-6799496
EcoR1 Capital, a director and 10% owner of AnaptysBio (ANABV), purchased 374,580 shares for approximately $17.2 million at an average price of $45.98 per share between November 16 and November 18, 2026. After these transactions, EcoR1 Capital's indirect holdings in AnaptysBio increased to 8,254,674 shares. This open-market purchase signifies a bullish stance from the insider.

Funds tied to a board member paid about $155M for shares of AnaptysBio (ANAB).

https://www.stocktitan.net/sec-filings/ANAB/schedule-13d-a-anaptysbio-inc-amended-major-shareholder-report-ddb4e6488542.html
EcoR1 Capital, LLC and Oleg Nodelman, who is also a board member of AnaptysBio (ANAB), have reported a beneficial ownership of 27.8% in the company. Funds associated with them purchased 8,254,674 shares for an aggregate price of $154,747,392.28. The reporting persons state that the acquisition was for investment purposes and they have no immediate plans for corporate actions but may recommend actions to management, the board, and stockholders.
Advertisement

After three days of fund buying in AnaptysBio (ANAB), one fund held 7,642,937 shares.

https://www.stocktitan.net/sec-filings/ANAB/form-4-anaptysbio-inc-insider-trading-activity-26e557846e55.html
AnaptysBio director and 10% owner Oleg Nodelman and 10% owner EcoR1 Capital, LLC reported three indirect fund purchases of ANAB common shares totaling 374,580 shares between November 16 and 18, 2026. The Qualified Fund, part of EcoR1 Capital, notably increased its holdings, ending with 7,642,937 shares after the November 18 transaction. These insider trades indicate a significant accumulation of shares by investment funds associated with the company's director.

Two parties report the same 924,640-share stake in AnaptysBio (ANAB).

https://www.stocktitan.net/sec-filings/ANAB/schedule-13g-a-anaptysbio-inc-amended-passive-investment-disclosure-ea7b2919c4a4.html
Sirenia Capital Management LP and Alex Silverstein have jointly reported a beneficial ownership of 924,640 shares in AnaptysBio, Inc. (ANAB), representing a 3.1% stake in the company. This disclosure was made in an amended passive investment filing (SCHEDULE 13G/A). The shares are held in an account managed by Sirenia, with both parties exercising shared voting and dispositive power.

AnaptysBio, Inc. (ANAB) Tops Q3 EPS by 75c

https://www.streetinsider.com/Earnings/AnaptysBio%2C+Inc.+%28ANAB%29+Tops+Q3+EPS+by+75c/27338354.html
AnaptysBio, Inc. (ANAB) reported strong financial results for Q3, significantly surpassing analyst expectations. The company announced an EPS of $0.11, which was $0.75 higher than the estimated ($0.64). Additionally, AnaptysBio's revenue for the quarter reached $30.27 million, exceeding the consensus estimate of $18.86 million.

AnaptysBio execs to present at major investor conferences in Nov-Dec 2026

https://pluang.com/en/news-feed/anaptysbio-ikut-konferensi-investor-november-2026
AnaptysBio announced that its executive team, including CEO Daniel Faga and CFO Chris Murphy, will participate in several investor conferences in November and December 2026. These events, including the UBS Global Biopharma, Piper Sandler Healthcare, and Evercore Healthcare conferences, will feature fireside chats and investor meetings to discuss company progress and financial collaborations for products like Jemperli and Quimilza. Live webcasts and replays will be available on the company's investor website.

Three AnaptysBio conference chats will be webcast, with replays available for at least 30 days.

https://www.stocktitan.net/news/ANAB/anaptys-announces-participation-in-upcoming-investor-frny5ckehdjh.html
AnaptysBio (ANAB) announced that its executives, CEO Daniel Faga and CFO Chris Murphy, will participate in three upcoming investor conferences in London, New York, and Miami. The conferences include the UBS Global Biopharma Conference 2026, Piper Sandler 38th Annual Healthcare Conference, and the 9th Annual Evercore Healthcare Conference, with fireside chats webcast and available for replay for at least 30 days. The company focuses on managing financial collaborations for Jemperli and Quimilza.
Advertisement

Anaptys Announces Participation in Upcoming Investor Conferences

https://uk.finance.yahoo.com/news/anaptys-announces-participation-upcoming-investor-212000704.html
AnaptysBio, Inc. announced that members of its executive team will participate in three upcoming investor conferences: the UBS Global Biopharma Conference, the Piper Sandler 38th Annual Healthcare Conference, and the 9th Annual Evercore Healthcare Conference. Daniel Faga, president and CEO, and Chris Murphy, CFO, will represent the company. Live webcasts of the fireside chats will be available on the investor section of the Anaptys website.

Did Rectal Cancer Approval Just Shift AnaptysBio's (ANAB) Investment Narrative?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-anab/anaptysbio/news/did-rectal-cancer-approval-just-shift-anaptysbios-anab-inves/amp
GSK, in collaboration with AnaptysBio, received FDA approval for Jemperli as the first immunotherapy for stage II and III MSI-H/dMMR locally advanced rectal cancer, potentially allowing patients to avoid surgery. This approval strengthens AnaptysBio's royalty-driven business model, which relies on partners like GSK to commercialize drugs. While analysts forecast a short-term dip in earnings, the expanded label for Jemperli adds a new royalty stream, contributing to the "good value" assessment of AnaptysBio on P/E and discounted cash flow.

AnaptysBio (ANAB) Gains From Jemperli Approval, Is The Royalty Upside Already Priced In?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-anab/anaptysbio/news/anaptysbio-anab-gains-from-jemperli-approval-is-the-royalty/amp
The FDA's approval of GSK's Jemperli for locally advanced rectal cancer has brought renewed attention to AnaptysBio (ANAB), which holds licensing rights and participates economically in the drug's success. Despite a recent slight dip, AnaptysBio's stock shows strong long-term momentum, with a 3-year total shareholder return of over 300%. The key question for investors is whether the potential royalty stream from Jemperli and other upcoming ventures, including ongoing litigation, is already factored into the current share price.

AnaptysBio, Inc. Estimates – NASDAQ:ANAB

https://www.tradingview.com/symbols/NASDAQ-ANAB/financials-estimates/
This article provides an overview of AnaptysBio, Inc. (NASDAQ: ANAB) financial estimates and actuals, accessible through TradingView. It highlights various financial data points including income statements, balance sheets, and cash flow, allowing users to compare actual results with analyst estimates. The platform offers tools for visualizing financial trends over time for informed investment decisions.

AnaptysBio Shares Fall 7.74% During GSK-Tesaro Post-Trial Hearing

https://www.tokenpost.com/news/regulation/36414
AnaptysBio shares dropped 7.74% on October 20 as a Delaware Court of Chancery held a post-trial hearing in its contract dispute with GSK and Tesaro over rights to the cancer drug Jemperli. GSK's U.S. depositary shares, however, closed 2.37% higher. A ruling in the high-stakes case, where AnaptysBio is seeking the return of its drug rights, is anticipated by early 2027.
Advertisement

AnaptysBio (ANAB) On Jemperli Approval Is The Royalty Story Still A Bargain

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-anab/anaptysbio/news/anaptysbio-anab-on-jemperli-approval-is-the-royalty-story-st/amp
AnaptysBio is back in focus following GSK’s new FDA approval for Jemperli, an antibody discovered and out-licensed by AnaptysBio. Despite recent share price fluctuations, the stock shows a strong 1-year return, and is considered by some investors to be 45% undervalued, trading at $49.24 against a fair value of $90. The investment thesis, however, depends heavily on a single oncology royalty and ongoing litigation.

AnaptysBio (ANAB) On Jemperli Approval Is The Royalty Story Still A Bargain

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-anab/anaptysbio/news/anaptysbio-anab-on-jemperli-approval-is-the-royalty-story-st
AnaptysBio (ANAB) is back in focus following GSK's FDA approval for Jemperli in advanced rectal cancer, given AnaptysBio's role in its discovery and out-licensing. Despite recent share price fatigue, the stock shows a strong 1-year return, and analysts consider it undervalued, with a fair value pegged closer to $90. The investment thesis largely relies on this single oncology royalty and ongoing litigation outcomes, which present both significant upside and risk.

AnaptysBio Announces FDA Approval of GSK’s Jemperli for MSI-H/dMMR Locally Advanced Rectal Cancer Based on AZUR-1 Data

https://www.quiverquant.com/news/AnaptysBio+Announces+FDA+Approval+of+GSK%E2%80%99s+Jemperli+for+MSI-H%2FdMMR+Locally+Advanced+Rectal+Cancer+Based+on+AZUR-1+Data
AnaptysBio announced that GSK has received FDA approval for Jemperli (dostarlimab) as the first immunotherapy for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer. This approval, based on AZUR-1 trial data, indicates that Jemperli can help patients avoid traditional treatments like chemotherapy, radiation, and surgery, which often have significant side effects. The AZUR-1 trial showed 68% of evaluable patients achieved sustained clinical complete responses at 12 months, with no disease recurrences reported among responders after a median follow-up of over two years.

A newly approved rectal cancer drug could help eligible patients avoid chemo, radiation and surgery

https://www.stocktitan.net/news/ANAB/jemperli-dostarlimab-approved-in-the-u-s-as-first-and-only-h1g4rvp1vhp9.html
GSK has received FDA approval for Jemperli (dostarlimab) as the first and only immunotherapy for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer. This approval is based on data from the AZUR-1 trial, which showed a significant proportion of patients achieved sustained clinical complete responses without detectable cancer after one year or more of treatment, potentially allowing them to avoid chemotherapy, radiation, and surgery. No disease recurrences have been reported among responders after a median follow-up of over two years.

Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer

https://www.globenewswire.com/de/news-release/2026/10/19/3383813/0/en/jemperli-dostarlimab-approved-in-the-u-s-as-first-and-only-immunotherapy-for-adults-with-msi-h-dmmr-locally-advanced-rectal-cancer.html
GSK has received U.S. FDA approval for Jemperli (dostarlimab) as the first and only immunotherapy for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer. This approval, based on AZUR-1 trial data, offers a treatment alternative that could help eligible patients avoid chemotherapy, radiation, and surgery, with no disease recurrences reported among responders after a median follow-up of over two years. AnaptysBio, Inc. manages the financial collaborations for Jemperli.
Advertisement

Form 144 ANAPTYSBIO For: 18 October By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-anaptysbio-for-18-october-93CH-4887231
This article announces the filing of Form 144 for ANAPTYSBIO (ANAB) on October 18, 2026. The stock experienced a -4.31% change on the reporting day. The publication is a concise financial market update from Investing.com.

Anaptysbio director Renton Hollings sells $249,371 of shares

https://www.investing.com/news/insider-trading-news/anaptysbio-director-renton-hollings-sells-249371-of-shares-93CH-4945355
AnaptysBio director Renton Hollings sold 5,000 shares of the company's common stock for $249,371 on October 1, 2026, through a pre-arranged trading plan. This transaction followed an impressive 113% return for AnaptysBio shares over the past year. Hollings also exercised options to acquire 5,000 shares, and still holds 10,995 shares directly, with options for 102,320 more.

Form 4 AnaptysBio Inc: Hollings Renton (Director) For: 1 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-4-anaptysbio-inc-hollings-renton-director-for-1-october-93CH-2732667
This article reports on a Form 4 filing by AnaptysBio Inc, indicating that Hollings Renton, a director, made a transaction on October 1st. The brief notice from Investing.com provides no further details on the nature of the transaction. The article also includes various market data and other news headlines.

Form 4 AnaptysBio Inc: Hollings Renton (Director) For: 1 October By Investing.com

https://uk.investing.com/news/stock-market-news/form-4-anaptysbio-inc-hollings-renton-director-for-1-october-93CH-4906500
This article reports on a Form 4 filing for AnaptysBio Inc., specifically mentioning that Hollings Renton, a director, made a filing for October 1st. The filing details are not provided within the article content, which primarily serves as a placeholder for the insider trading report.

AnaptysBio (ANAB) Slides As Royalty And Delaware Debate Tests Whether Shares Are A Bargain

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-anab/anaptysbio/news/anaptysbio-anab-slides-as-royalty-and-delaware-debate-tests
AnaptysBio (ANAB) has experienced a share price slide due to investor re-evaluation of its royalty-focused biotech model, valuation, and a legal challenge in Delaware. Despite recent declines, the company still shows strong long-term returns. Analysts currently view ANAB as 49% undervalued, with a fair value of $90, contingent on favorable outcomes regarding its Jemperli royalties and the Delaware legal case.
Advertisement

AnaptysBio earnings beat by $5.58, revenue topped estimates

https://uk.investing.com/news/earnings/anaptysbio-earnings-beat-by-558-revenue-topped-estimates-4903816
AnaptysBio (NASDAQ: ANAB) reported strong first-quarter results, with EPS of $5.11, significantly beating analyst estimates of $-0.47 by $5.58. The company also surpassed revenue expectations, bringing in $27.49 million against a consensus estimate of $14.06 million. Despite recent volatility, with a -34.18% change in the last three months, the stock has seen a 46.48% increase over the past year, and its financial health is rated as "good performance" by InvestingPro.

AnaptysBio Q3 2026 Earnings Date and Estimates

https://www.marketbeat.com/earnings/reports/2026-11-3-anaptysbio-inc-stock/
AnaptysBio (NASDAQ: ANAB) is projected to announce its Q3 2026 earnings after market close on Tuesday, November 3, 2026, with a conference call scheduled for November 4, 2026, at 4:00 PM ET. Analysts anticipate an EPS of -$1.84 on revenues of $25.56 million, a significant decrease compared to the previous year's Q3 results. The company has a strong track record of beating EPS estimates, doing so in 7 of its last 8 quarters.

AnaptysBio, Inc. (AN6.F) Analyst Insights, Price Targets & Recommendations

https://ca.finance.yahoo.com/quote/AN6.F/analyst-insights/
The article provides an overview of analyst insights, price targets, and recommendations for AnaptysBio, Inc. (AN6.F). It lists recent analyst actions including upgrades, downgrades, and reiterations from firms like JP Morgan, HC Wainwright & Co., Leerink Partners, TD Cowen, and UBS. The stock's current trading information is also displayed, showing a slight gain.

AnaptysBio (NASDAQ:ANAB) Director Sells 5,000 Shares of Company Stock

https://www.marketbeat.com/instant-alerts/insider-anaptysbio-nasdaq-anab-director-sells-5000-shares-of-company-stock-2026-10-02/
AnaptysBio (NASDAQ:ANAB) director Hollings Renton sold 5,000 shares of the company's stock for $249,350, reducing his holdings by 31.26%. The sale, executed under a Rule 10b5-1 plan, comes as AnaptysBio reported strong quarterly earnings of $5.11 per share, significantly beating estimates, and revenue of $27.49 million, also exceeding expectations. Despite a "Moderate Buy" consensus rating and an average price target of $77.79 from analysts, the stock is trading near $48.53, well below its 52-week high.

Leerink Partners maintains Outperform rating on AnaptysBio, $81 price target

https://www.tradingview.com/news/tradingview:cabe4da579644:0-leerink-partners-maintains-outperform-rating-on-anaptysbio-81-price-target/
Leerink Partners has reiterated its Outperform rating on AnaptysBio (ANAB) with an $81 price target, indicating a potential 50.2% upside from its previous close. This positive outlook is driven by AnaptysBio's strong pipeline development, including promising candidates for autoimmune and inflammatory diseases, and favorable market sentiment due to the anticipated resolution of a GSK dispute and Jemperli's sales growth. The company's defined catalyst path with upcoming clinical readouts further enhances investor confidence.
Advertisement

AnaptysBio (ANAB) Flags Positive AZUR 1 Data With Approval And Legal Timelines

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-anab/anaptysbio/news/anaptysbio-anab-flags-positive-azur-1-data-with-approval-and/amp
AnaptysBio reported positive interim data from its AZUR-1 trial for Jemperli in rectal cancer, outlining regulatory timelines for Jemperli and Quimilza, and new information on ongoing litigation. The company's future revenue visibility hinges on successful execution of regulatory approvals and a clear outcome from its litigation by late 2026/early 2027. This progress supports AnaptysBio's out-licensing model, which relies on partners for drug advancement and commercialization.

Bank of America Corp DE Makes New $28.20 Million Investment in AnaptysBio, Inc. $ANAB

https://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-makes-new-2820-million-investment-in-anaptysbio-inc-anab-2026-09-23/
Bank of America Corp DE has made a new $28.20 million investment in AnaptysBio, Inc. (NASDAQ:ANAB), acquiring 417,812 shares, representing a 1.41% stake in the biotechnology company. Other institutional investors like BlackRock also increased their holdings. AnaptysBio has a "Moderate Buy" consensus rating with a target price of $79.85, and recently reported strong Q2 earnings, exceeding revenue and EPS estimates.

AnaptysBio, Inc. (ANAB) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/ANAB/
AnaptysBio, Inc. (ANAB) is a clinical-stage biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases. The company's stock is currently trading at $50.74, down 5.91%, with a 1-year return of 262.68%. Key products include Rosnilimab, ANB033, and Imsidolimab, with various programs in clinical trials and collaborations with GSK and Vanda.

AnaptysBio Swings to Q2 Profit as Revenue Rises; Shares Gain After Hours

https://finance.yahoo.com/markets/stocks/articles/anaptysbio-swings-q2-profit-revenue-204345941.html
AnaptysBio (ANAB) reported a significant swing to profit in its second quarter, achieving $5.11 per diluted share. This positive financial performance, coupled with increased revenue, led to a rise in the company's shares in after-hours trading. The detailed report of their Q2 earnings was released late Monday.

AnaptysBio stock rating maintained at Outperform by Wolfe Research

https://m.investing.com/news/analyst-ratings/anaptysbio-stock-rating-maintained-at-outperform-by-wolfe-research-93CH-4882440?ampMode=1
Wolfe Research has reiterated its Outperform rating on AnaptysBio Inc. (NASDAQ:ANAB) with a $78.00 price target, driven by its analysis of the ongoing litigation between AnaptysBio and GSK concerning contractual obligations related to the drug Jemperli. The firm noted ambiguities in the amendment agreement but suggests AnaptysBio may have a strong case for reversion of rights given Tesaro's alleged failure to meet commercial efforts. Other recent analyst actions include a reduced price target from TD Cowen and new coverage with a Buy rating from H.C. Wainwright.
Advertisement

AnaptysBio earnings on deck: Can Jemperli offset revenue slide? By Investing.com

https://ng.investing.com/news/stock-market-news/anaptysbio-earnings-on-deck-can-jemperli-offset-revenue-slide-93CH-2679573
AnaptysBio Inc. is reporting its second-quarter results, with investor focus on whether Jemperli royalty growth can counteract an anticipated revenue decline. The company's transformation into a royalty-management entity will be scrutinized, as analysts expect a loss of 13 cents per share on $20.2 million in revenue, despite strong analyst ratings and a significant stock surge since its spin-off. Investors will also monitor the outlook for imsidolimab and capital allocation strategies, including a $100 million stock repurchase plan.

1,844,049 Shares in AnaptysBio, Inc. $ANAB Bought by BlackRock Inc.

https://www.marketbeat.com/instant-alerts/filing-1844049-shares-in-anaptysbio-inc-anab-bought-by-blackrock-inc-2026-08-29/
BlackRock Inc. has acquired 1,844,049 shares of AnaptysBio, Inc. (NASDAQ:ANAB) in the second quarter, representing a 6.23% ownership stake valued at approximately $124.5 million. AnaptysBio, a clinical-stage biotechnology company, has a market capitalization of $1.67 billion and its shares opened at $56.28. Despite some recent analyst downgrades, the stock maintains a "Moderate Buy" consensus rating with an average price target of $80.00.

Empowered Funds LLC Makes New $13.91 Million Investment in AnaptysBio, Inc. $ANAB

https://www.marketbeat.com/instant-alerts/filing-empowered-funds-llc-makes-new-1391-million-investment-in-anaptysbio-inc-anab-2026-08-29/
Empowered Funds LLC has made a new $13.91 million investment in AnaptysBio, Inc. (NASDAQ:ANAB), acquiring 206,010 shares during the second quarter, representing about 0.70% of the company. Other institutional investors like Bank of America and HSBC also initiated positions. AnaptysBio shares opened at $56.28, down 1.8%, with analysts maintaining a "Moderate Buy" consensus rating and an average price target of $80.00.

Palo Alto Investors LP Purchases Shares of 603,489 AnaptysBio, Inc. $ANAB

https://www.marketbeat.com/instant-alerts/filing-palo-alto-investors-lp-invests-4074-billion-in-anaptysbio-inc-anab-2026-08-28/
Palo Alto Investors LP has acquired 603,489 shares of AnaptysBio, Inc. (NASDAQ:ANAB) during the second quarter, a stake valued at approximately $40.7 million, making it their fifth largest position. This acquisition represents about 2.04% of the biotechnology company, which focuses on developing therapeutic antibody product candidates. Despite a "Moderate Buy" consensus rating and an average price target of $80 from analysts, the stock traded at $56.28 with a market capitalization of $1.67 billion.

Hsbc Holdings PLC Purchases Shares of 216,949 AnaptysBio, Inc. $ANAB

https://www.marketbeat.com/instant-alerts/filing-hsbc-holdings-plc-purchases-shares-of-216949-anaptysbio-inc-anab-2026-08-28/
Hsbc Holdings PLC recently acquired 216,949 shares of AnaptysBio, Inc. (NASDAQ:ANAB) in the second quarter, a new position valued at approximately $14.9 million, representing 0.73% of the company. Other institutional investors like JPMorgan Chase, AQR Capital, Creative Planning, Russell Investments, and Arrowstreet Capital also increased their holdings. AnaptysBio, a clinical-stage biotechnology company, currently holds a "Moderate Buy" consensus rating from analysts, with a target price of $80.00, despite a negative price-to-earnings ratio.
Advertisement

Deutsche Bank AG Makes New Investment in AnaptysBio, Inc. $ANAB

https://www.marketbeat.com/instant-alerts/filing-deutsche-bank-ag-makes-new-investment-in-anaptysbio-inc-anab-2026-08-27/
Deutsche Bank AG initiated a new investment in AnaptysBio, Inc. (NASDAQ:ANAB) during the second quarter, purchasing 46,884 shares valued at approximately $3.17 million. Other institutional investors like Vanguard and State Street also increased their holdings. AnaptysBio holds a "Moderate Buy" consensus from analysts with an average price target of $80.

Connor Clark & Lunn Investment Management Ltd. Takes Position in AnaptysBio, Inc. $ANAB

https://www.marketbeat.com/instant-alerts/filing-connor-clark-lunn-investment-management-ltd-takes-position-in-anaptysbio-inc-anab-2026-08-27/
Connor Clark & Lunn Investment Management Ltd. has taken a significant new position in AnaptysBio, Inc. (NASDAQ:ANAB), purchasing 141,026 shares valued at approximately $9.5 million during the second quarter. This move is part of broader institutional interest, with several other hedge funds, including BlackRock Inc., also acquiring stakes in the biotechnology company. Analyst sentiment for AnaptysBio remains largely positive, with a "Moderate Buy" consensus and an average price target of $80.00, significantly higher than the stock's current price.

TD Cowen Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $70

https://www.moomoo.com/news/post/75176154/td-cowen-maintains-anaptysbio-anabus-with-buy-rating-cuts-target
TD Cowen has reiterated its Buy rating for AnaptysBio (ANAB.US) but has adjusted its price target downwards to $70. This revision indicates a maintained positive outlook on the company's stock despite a lower valuation projection.

ANAB Reiterates Buy by HC Wainwright & Co. -- Price Target Maintained at $95

https://www.gurufocus.com/news/9049761/anab-reiterates-buy-by-hc-wainwright-co-price-target-maintained-at-95
HC Wainwright & Co. has reiterated a Buy rating for AnaptysBio (ANAB) with a maintained price target of $95.00, reflecting confidence in its growth potential despite its current GF Score™ of 40. The company, which focuses on developing innovative antibody therapies, has a market cap of $1.69 billion and active clinical trials. While analysts see significant upside, the stock's current valuation metrics suggest it may be overvalued relative to historical performance, warranting careful consideration from investors.

AnaptysBio (NASDAQ:ANAB) Given Buy Rating at HC Wainwright

https://www.marketbeat.com/instant-alerts/anaptysbio-nasdaqanab-given-buy-rating-at-hc-wainwright-2026-08-24/
HC Wainwright has reiterated its "Buy" rating for AnaptysBio (NASDAQ:ANAB) and set a price target of $95, indicating a potential upside of 66.7% from its current price. While the stock fell 1.3% in mid-day trading, analyst sentiment remains largely positive with a "Moderate Buy" consensus rating and an average price target of $82, with several institutional investors recently increasing their stakes. Other analysts have also adjusted their ratings and price targets, contributing to the overall positive outlook despite some downgrades.
Advertisement

Bank of America Corp DE Boosts Stock Position in AnaptysBio, Inc. $ANAB

https://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-boosts-stock-position-in-anaptysbio-inc-anab-2026-08-17/
Bank of America Corp DE significantly increased its stake in AnaptysBio, Inc. (NASDAQ:ANAB) by 283.2% in the first quarter, acquiring 370,319 additional shares. The firm now holds 501,086 shares valued at approximately $27.8 million, representing 1.72% of the company. Other institutional investors, including Affinity Asset Advisors and Royal Bank of Canada, also boosted their positions, while analysts maintain a "Moderate Buy" consensus rating for AnaptysBio with an average price target of $82.00.

Sirenia Capital discloses 5.0% AnaptysBio (ANAB) ownership in Schedule 13G/A

https://www.stocktitan.net/sec-filings/ANAB/schedule-13g-a-anaptysbio-inc-amended-passive-investment-disclosure-80abae4a6120.html
Sirenia Capital Management LP and Alex Silverstein have reported a beneficial ownership of 5.0% in AnaptysBio, Inc. (ANAB) common stock, as detailed in a Schedule 13G/A filing. This stake amounts to 1,491,959 shares, based on 29,608,481 shares outstanding as of June 22, 2026. The shares are held in a managed account of Point72 Associates II, LLC, with Sirenia and Mr. Silverstein exercising shared voting and dispositive power.

Is AnaptysBio (ANAB) Undervalued After Its Recent Share Price Swings?

https://www.sahmcapital.com/news/content/is-anaptysbio-anab-undervalued-after-its-recent-share-price-swings-2026-08-10
AnaptysBio (ANAB) has experienced significant share price swings but is considered undervalued by analysts and intrinsic value estimates, trading at a discount despite strong longer-term momentum. The company, focused on immunology therapeutics, is projected to have a fair value of $90 due to rising royalty streams, a future revenue doubling from a loan expiration, and potential upside from a lawsuit. However, investors are cautioned to consider risks like the outcome of GSK litigation and potential deviations in royalty and clinical expectations.

AnaptysBio earnings ahead: Can royalty revenue offset spinoff volatility? By Investing.com

https://za.investing.com/news/earnings/anaptysbio-earnings-ahead-can-royalty-revenue-offset-spinoff-volatility-93CH-4417062
AnaptysBio, now operating as Anaptys, is set to release its Q2 earnings, marking its first full quarter as a pure-play royalty management company after spinning off its drug development operations. Analysts predict a loss of 13 cents per share on $20.2 million in revenue, a significant improvement in losses but a revenue decline from the previous quarter. Investors will closely watch Jemperli royalty revenue trajectory and operating margin execution to see if the simplified model can deliver promised profitability and stability despite wavering analyst confidence and potential quarterly volatility.

AnaptysBio (NASDAQ: ANAB) awards 16,667 performance stock units to its CMO

https://www.stocktitan.net/sec-filings/ANAB/form-4-anaptysbio-inc-insider-trading-activity-471448e98861.html
AnaptysBio (NASDAQ: ANAB) has awarded 16,667 performance stock units (PSUs) to its Chief Medical Officer, Paul F. Lizzul. These PSUs were granted on March 12, 2026, after achieving certified performance criteria, with each unit representing a right to one share of common stock. The units will vest 50% on March 12, 2027, and 50% on March 12, 2028, contingent on Lizzul's continued employment.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement